Patrick W. McLaughlin, MD, discusses balancing the therapeutic effects of androgen deprivation therapy (ADT) with the impact of quality of life (QOL). He examines the best timing and radiotherapy regimen combination to pair with ADT, as well as properly assessing individual patients’ risk factors and disease severity when choosing treatment options.
Read More
Michael J. Zelefsky, MD, examines the clinical issue of rectal toxicity in prostate cancer patients treated with prostate radiotherapy. He reviews the current findings on the efficacy of rectal spacers in reducing rectal, gastrointestinal, and genitourinary toxicities in these patients.
Read More
Abraham Morgentaler, MD, FACS, describes the phenomenon of testosterone flare following prostate cancer treatment with luteinizing hormone-releasing hormone (LHRH) agonists and argues that this flare does not necessarily cause disease progression. He also discusses the effects of testosterone therapy in patients with untreated prostate cancer.
Read More
Jason A. Efstathiou, MD, DPhil, emphasizes the need for continued clinical trials to refine therapy options for high-risk and locally advanced prostate cancer patients. He reviews six major considerations regarding the current state of external beam radiation therapy (EBRT) for the treatment of high-risk disease.
Read More
Daniel P. Petrylak, MD, analyzes the current status of immunotherapy for prostate cancer, reviewing available options, emerging combination therapies, and immunotherapy clinical trials. He also emphasizes the impact of PD-L1 expression, microsatellite instability, and other mutations in prostate cancer on patient responses to immunotherapy.
Read More